Ono Pharmaceutical Enters into Collaboration Agreement with Domain Therapeutics and University of Montreal for GPCR Targeted Drug Discovery
Under this agreement, Ono will collaborate with Domain and UdM using bioSens-All technology’s GPCR drug discovery platform, licensed from Domain from UdM, and their expertise in medicinal chemistry and pharmacology GPCR to design and optimize innovative small molecules against a selected GPCR. as a therapeutic target by Ono, for a future drug development program.
Ono will have exclusive worldwide rights to develop and commercialize any pharmaceutical products resulting from the drug discovery collaboration. Ono will provide Domain and UdM with an upfront payment, research funding for collaborative research programs, milestones based on the success of research and development progress, and royalties from future sales.
We highly value Domain and UdM’s bioSens-All technology platform for the detection of GPCR proximal signaling pathways,” said
At Domain, we are delighted to strengthen our long-term relationship with Ono pharma and UdM,” commented
Very early on, we accumulated great expertise on GPCR and its pharmacology,” notes
About the GPCR
GPCRs are members of a class of G protein-conjugated cell surface receptors, whose signaling pathway is initiated by binding between the receptor and a hormone or bioactive molecule. GPCR-targeted therapies include major classes of drugs in many disease areas, including CNS, metabolic, cardiovascular, respiratory, urinary, and gastrointestinal diseases.
About Domain Therapeutics
Domain Therapeutics is a biopharmaceutical company located in
bioSens-All provides drug discovery teams with the ability to interrogate direct proximal signaling events covering key effectors engaged during GPCR activation. bioSens-All enables deeper understanding of proximal signaling profiles, providing a functional readout to assess small molecule or antibody activities based on physiologically relevant signaling information. For more information : https://www.domaintherapeutics.com/
About the University of
Deeply rooted in
Email: [email protected]